HOPE Phase I/II
The Halt cardiomyOPathy progrEssion in Duchenne (HOPE) Phase I/II trial will evaluate CAP-1002 in patients with Duchenne muscular dystrophy associated cardiomyopathy.
The HOPE-Duchenne trial is evaluating CAP-1002 for the first time in boys and young men with Duchenne muscular dystrophy (DMD) who have significant cardiac involvement. Cardiomyopathy is currently the leading cause of death in patients with DMD, having recently surpassed respiratory causes as a result of treatment improvements for that aspect of the disease. In this trial, subjects received CAP-1002 in all three coronary arteries using the same non-stop flow technique used in the DYNAMIC trial. The trial is being funded, in part, through the support of the California Institute for Regenerative Medicine (CIRM).
The Phase I/II HOPE-Duchenne trial is designed as a randomized open-label usual care controlled multi-center study evaluating the safety and preliminary efficacy of CAP-1002 in 25 subjects.
For more information please click here for the 12-month Results of the HOPE Clinical Trial Conference Call presented at the AHA Scientific Sessions 2017.
Please visit ClinicalTrials.gov for more information regarding the HOPE clinical trial.